Ubiquitomics: an overview and future by Vere, G, Kealy, R, Kessler, B, Pinto-Fernandez, A

Targeting the ubiquitylation and ISGylation machinery for the treatment of COVID-19 by Vere, G, Alam, MR, Farrar, S, Kealy, R, Kessler, BM, O’Brien, DP, Pinto-Fernández, A

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial by Kealy R. Ham, David W. Boldt, Michael T. McCurdy, Laurence W. Busse, Raphael Favory, Michelle N. Gong, Ashish K. Khanna, Stefan N. Chock, Feng Zeng, Lakhmir S. Chawla, George F. Tidmarsh, Marlies Ostermann

Get full text

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial by Patrick M. Wieruszewski, Rinaldo Bellomo, Laurence W. Busse, Kealy R. Ham, Alexander Zarbock, Ashish K. Khanna, Adam M. Deane, Marlies Ostermann, Richard G. Wunderink, David W. Boldt, Stew Kroll, Chuck R. Greenfeld, Tony Hodges, Jonathan H. Chow, the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators

Get full text

Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock by Daniel E. Leisman, Damian R. Handisides, Lakhmir S. Chawla, Timothy E. Albertson, Laurence W. Busse, David W. Boldt, Adam M. Deane, Michelle N. Gong, Kealy R. Ham, Ashish K. Khanna, Marlies Ostermann, Michael T. McCurdy, B. Taylor Thompson, James S. Tumlin, Christopher D. Adams, Tony N. Hodges, Rinaldo Bellomo

Get full text